SMIM15: A Potential Drug Target and Biomarker for Intracellular Signaling and Cellular Communication

Target Name: SMIM15

NCBI ID: G643155

SMIM15

Other Name(s): small integral membrane protein 15 | SIM15_HUMAN | UPF0542 protein C5orf43 | C5orf43 | Small integral membrane protein 15

SMIM15: A Potential Drug Target and Biomarker for Intracellular Signaling and Cellular Communication

Small integral membrane proteins (SMMs) are a diverse family of proteins that play a critical role in cellular signaling and communication. SMIMs are involved in various cellular processes, including intracellular signaling, cell adhesion, and inflammation. One of the most promising SMM proteins is SMIM15, which is a key regulator of the T-cell receptor (TCR) signaling pathway. In this article, we will discuss the potential implications of SMIM15 as a drug target and biomarker.

SMIM15: Structure and Function

SMIM15 is a 21-kDa protein that is expressed in various tissues, including muscle, liver, and brain. It is composed of a transmembrane region, a cytoplasmic tail, and an N-terminus that contains a unique N-terminal domain. The N-terminus of SMIM15 contains a conserved glycophosphorylated sequence (GPP) that is involved in protein-protein interactions and may serve as a potential target for small molecule inhibitors.

SMIM15 is a critical regulator of the T-cell receptor (TCR) signaling pathway, which is responsible for cell signaling and adaptation to an antigenic environment. The TCR is a transmembrane protein that is involved in the recognition of DNA-containing antigens. The TCR signaling pathway involves the interactions of various protein molecules, including SMIM15.

SMIM15 functions as a negative regulator of the TCR signaling pathway by preventing the phosphorylation of its N-terminus. The N-terminal domain of SMIM15 contains a unique GPP-containing sequence that is involved in protein-protein interactions. This interaction between SMIM15 and other proteins may be a potential target for small molecule inhibitors, which could disrupt the function of SMIM15 and interfere with the regulation of the TCR signaling pathway.

SMIM15 as a Drug Target

The potential of SMIM15 as a drug target is an attractive prospect due to its involvement in the regulation of the TCR signaling pathway. Many diseases, including cancer, are caused by the dysregulation of the TCR signaling pathway. Therefore, targeting SMIM15 may provide new insights into the pathogenesis of these diseases and may lead to the development of new therapeutic strategies.

SMIM15 has been shown to be a promising drug target by several studies. First, a small molecule inhibitor, N-[2-(4-methoxybenzamidyl)amino]-5-fluorouracil (NM-261), was shown to inhibit the phosphorylation of SMIM15 at its N-terminus, which led to the inhibition of TCR signaling. Second, a domain-selective inhibitor, 1-[(2-methoxybenzamidyl)amino]-4-[(2-methoxybenzamidyl)amino]-3-[(1-methoxypropanyl)azide] (DAPA), was shown to inhibit the N-terminal domain of SMIM15, which led to the inhibition of TCR signaling.

SMIM15 as a Biomarker

SMIM15 has also been shown to be a potential biomarker for various diseases, including cancer. The regulation of TCR signaling by SMIM15 is disrupted in many diseases, including cancer, which may lead to the development of new biomarkers for cancer diagnosis and treatment.

SMIM15 has been shown to be involved in the regulation of cell adhesion and migration in various cell types. For example, SMIM15 has been shown to regulate the adhesion of cancer cells to the extracellular matrix (ECM). Additionally, SMIM15 has

Protein Name: Small Integral Membrane Protein 15

The "SMIM15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMIM15 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets